Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Children/juveniles, 2-17 years of age.~* Polyarticular-course juvenile idiopathic arthritis (pcJIA) ≥ 6 months duration.~* Active disease (≥ 5 active joints, ≥ 3 with limitation of motion).~* Inadequate response to or inability to tolerate methotrexate.~* Methotrexate, oral corticosteroids, and non-steroidal anti-inflammatory drugs (NSAID) at stable dose(at least 8, 4, and 2 weeks,respectively) prior to baseline.~* Biologics discontinued, between at least 1 and 20 weeks prior to baseline, depending on biologic.~Exclusion Criteria:~* Auto-immune, rheumatic disease or overlap syndrome other than pcJIA.~* Wheelchair bound or bedridden.~* Intra-articular, intramuscular, intravenous, or long-acting corticosteroids within 4 weeks prior to baseline.~* Disease-modifying anti-rheumatic drugs (DMARD) (other than methotrexate) within 4 weeks prior to baseline.~* Previous treatment with tocilizumab.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 10 mg/kg in patients weighing < 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
- Tocilizumab 8 mg/kg in patients weighing < 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
- Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo to tocilizumab intravenously every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).